BMRN
Biomarin Pharmaceutical Inc
64.10$
+0.2%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 57.2% | 29.2% | 35.3% | 47.6% | 46.4% | 41.4% | 40.1% | 37.9% | 43.2% | 43.2% | 46.3% | 52.1% | |
| 35.2% | 10.6% | 10.1% | 12.9% | 11.2% | 9.3% | 11.1% | 9.8% | 11.4% | 11.0% | 13.5% | 17.3% | |
| 38.0% | 15.9% | 19.6% | 30.1% | 24.5% | 16.1% | 18.2% | 16.9% | 20.3% | 15.7% | 16.3% | 20.6% | |
| 5.8% | 4.4% | 5.4% | 5.6% | 7.7% | 8.0% | 7.7% | 6.2% | 7.2% | 9.3% | 9.5% | 12.0% | |
| 8.0% | 7.3% | 8.8% | 10.3% | 12.0% | 14.5% | 11.9% | 12.9% | 14.0% | 16.2% | 17.6% | 17.1% | |
| 21.0% | 18.9% | 19.9% | 19.4% | 21.4% | 21.6% | 17.7% | 17.2% | 17.5% | – | – | – | |
| 2.2% | 5.3% | 4.9% | 4.3% | 4.5% | 4.2% | 3.4% | 3.3% | 3.1% | 2.9% | 2.8% | 2.6% | |
| 6.3% | 18.3% | 13.8% | 11.2% | 11.1% | 9.7% | 7.1% | 6.5% | 5.3% | 4.3% | 3.7% | 2.8% | |
| 38.6% | 35.6% | 31.3% | 39.4% | 33.0% | 33.4% | 29.8% | 28.9% | 27.8% | 27.6% | 19.0% | 19.8% | |
| 9.5% | 11.9% | 10.9% | 17.6% | 11.8% | 19.9% | 8.4% | 9.0% | 9.2% | 17.2% | 8.7% | 10.0% | |
| 25.8% | 17.8% | 0.6% | 7.8% | – | 7.9% | 0.2% | 0.2% | 0.2% | 7.3% | 0.3% | 0.1% | |
| 9.5% | 10.5% | 4.8% | 3.6% | 4.7% | 5.1% | 3.3% | 3.2% | 3.6% | 4.6% | 3.4% | 4.1% | |
| 26.4% | 17.8% | 16.4% | 17.6% | 18.8% | 10.4% | 18.4% | 18.0% | 17.0% | 8.7% | 8.5% | 7.9% | |
| 61.4% | 64.4% | 68.7% | 60.6% | 67.0% | 66.6% | 70.2% | 71.1% | 72.2% | 72.4% | 81.0% | 80.2% | |
| -34.1% | -27.4% | -37.8% | -35.3% | -38.3% | -36.7% | -14.7% | -15.4% | -12.4% | -9.1% | -2.8% | 2.0% | |
| 5.9% | 4.3% | 4.1% | 3.8% | 4.0% | 3.8% | 3.3% | 3.0% | 3.0% | 2.8% | 2.8% | 2.6% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.